Focus: SI-BONE is a publicly traded medical device company specializing in minimally invasive sacroiliac joint fusion systems, with a flagship iFuse implant platform addressing musculoskeletal pain. The company generated $139M in revenue in FY 2025 and has expanded into adjacent spinal fusion indications.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow SI-BONE to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from SI-BONE's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for SI-BONE
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
FDA clears a spinal fusion device for people with weak bones. It's SI-BONE's first such product for use beyond the pelvis. - Stock Titan
FDA clears a spinal fusion device for people with weak bones. It's SI-BONE's first such product for use beyond the pelvis. Stock Titan
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite - GlobeNewswire
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite GlobeNewswire
8-K Filing: CARLSMED, INC. (CARL) (CIK 0001794546) — EX-99.1
EX-99.1
8-K Filing: Profound Medical Corp. (PROF) (CIK 0001628808) — EXHIBIT 99.1
EXHIBIT 99.1
Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX) The Globe and Mail
Is This Biotech Stock a Buy After a Groundbreaking Approval? - AOL.com
Is This Biotech Stock a Buy After a Groundbreaking Approval? AOL.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Minimally invasive sacroiliac joint fusion: Primary endpoint results from the prospective, multicenter STACI study.
Differential Diagnosis of Posterior Buttock Pain: A Conceptual Review Based on Topographic Localization of Pain, Is It Really the Sacroiliac Joint?
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo